Overview

* Arbutus Q3 revenue and net income missed analyst expectations

* Company reports 46% of Phase 2a patients discontinued treatment in imdusiran trials

* Arbutus continues litigation against Moderna and Pfizer/BioNTech over LNP technology

Outlook

* Favorable claim construction ruling in Pfizer-BioNTech litigation, Moderna trial set for March 2026

* 46% of Phase 2a patients discontinued treatment, showing potential efficacy of imdusiran

Result Drivers

* COST REDUCTIONS - Decrease in R&D expenses due to restructuring and focus on imdusiran and AB-101

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $500,000 $1.27

Revenue mln (3

Analysts

)

Q3 Net Miss -$7.70 -$6.94

Income mln mln (2

Analysts

)

Q3 Cash $93.70

& mln

Investme

nts

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Arbutus Biopharma Corp ( ABUS ) is $5.00, about 3.2% above its November 12 closing price of $4.84

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)